Sibaja JJD

Language: Spanish
References: 17
Page: 513-516
PDF size: 218.56 Kb.

ABSTRACT

An adequate initial antimicrobial therapy is fundamental in determining the course of severe bacterial infections. The emergence of carbapenems, such as broad- spectrum β-lactam antibiotics, constitutes an option to consider as initial empiric therapy for the management of severe bacterial infections in hospitalized patients, supported by its proven therapeutic efficacy, safety and tolerability.

REFERENCES

1. Datos de Archivo, AstraZeneca, 2008.

2. Electronic medicines compendium. Meronem IV 500mg & 1g, summary of product characteristics from the electronic medicines compendium [online]. Disponible en URL: http:// www.emc medicines.org.uk/ [Accesado 2011 Dic 05]

3. Jones RN, Mendes C, Turner PJ, et al. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997- 2004. Diagn Microbiol Infect Dis 2005 Dec; 53 (4): 247-56MerremRM IV (meropenem for injection): US Prescribing Information. AstraZeneca, 2007 Feb

4. Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against gram- negative bacilli with various betalactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005; 52: 71-4

5. Kollef MH. Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time. Drugs 2003; 63 (20): 2157

6. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000 Sep; 31 Suppl. 4: S131-8

7. Lowe MN, Lamb HM. Meropenem: an updated review of its use in the management of intra-abdominal infections. Drugs 2000;60: 619-46

8. Merrem/MeronemTM (IV, 500mg, 1g): core data sheet. AstraZeneca, 2006 Sep

9. MerremRM IV (meropenem for injection): US Prescribing Information. AstraZeneca, 2007 Feb

10. Moon YSK, Chung KC, Gill MA. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin Infect Dis 1997 Feb; 24 (Suppl. 2): 249-55

11. Nichols RL, Smith JW, Geckler RW, et al. Meropenem versus imipenem/cilastin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 1995 Apr; 88 (4):397-404

12. Rello J, Gallego M, Mariscal D, et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997 Jul; 156 (1): 196-200

13. Shah PM, Heller A, Fuhr HG, et al. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients. Infection 1996; 24 (6): 480-4

14. Spriet I, Goyens J, Meersseman W, et al. Interaction between valproate and meropenem: a retrospective study. Ann Pharmacother 2007; 41 (7-8): 1130-6

15. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005 Nov 15; 41 (10): 1373-406

16. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamaseproducing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007 Jun; 51 (6): 1987-94

17. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67 (7): 1027-52